GLP-1 receptor agonists (semaglutide and liraglutide) and tirzepatide carry a boxed warning about thyroid C-cell tumors in rodents and are contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2)
doi: 10.3389/fmed.2026.1763185 Received 08 December 2025 Revised 20 January 2026 Accepted 26 January 2026 Published 12 February 2026 Volume 13 - 2026 Edited by Jianbin Zhang, Dalian Medical University, China Reviewed by Theodoros Androutsakos, National and Kapodistrian University of Athens, Greece Feng Zhang, Nanjing University of Chinese Medicine, China Updates Copyright 2026 Lu and Yang
BPC-157 operates through multiple simultaneous pathways that collectively restore vascular function and tissue integrity
Drinking on semaglutide carries specific risks related to delayed gastric emptying and blood sugar effects, but these are semaglutide effects, not B12 effects
FDA approves Afrezza to treat diabetes
Optimal Health Medical will continue to monitor official FDA materials rather than relying on headlines alone
